Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 547,178 | 420,146 | 645,361 | 193,617 | 180,895 |
| Marketable Securities | 988,984 | 664,009 | 1,045,257 | 433,182 | 899,636 |
| Receivables | 43,011 | 18,760 | 34,002 | 23,334 | 8,298 |
| Inventories | 56,348 | 24,068 | N/A | N/A | N/A |
| TOTAL | $1,715,864 | $1,200,696 | $1,764,740 | $671,877 | $1,105,388 |
| Non-Current Assets | |||||
| PPE Net | 425,179 | 320,658 | 181,900 | 114,572 | 27,812 |
| Investments And Advances | 14,825 | 44,825 | 43,919 | 474,799 | 251,839 |
| Other Non-Current Assets | 239,266 | 8,623 | 4,171 | 1,562 | 1,471 |
| TOTAL | $679,270 | $374,106 | $229,990 | $590,933 | $281,122 |
| Total Assets | $2,395,134 | $1,574,802 | $1,994,730 | $1,262,810 | $1,386,510 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 49,884 | 59,708 | 28,355 | 54,465 | 16,787 |
| Accrued Expenses | 197,201 | 112,719 | 72,203 | 42,118 | 28,798 |
| TOTAL | $352,594 | $179,494 | $144,251 | $131,699 | $62,099 |
| Non-Current Liabilities | |||||
| Long Term Debt | 0 | 30,000 | 30,000 | 150,000 | 0 |
| Deferred Revenues | 77,821 | 7,067 | 43,693 | 35,116 | 16,514 |
| Other Non-Current Liabilities | 285,465 | 4,965 | 4,347 | 3,067 | 1,301 |
| TOTAL | $603,848 | $93,343 | $84,048 | $210,890 | $59,697 |
| Total Liabilities | $956,442 | $272,837 | $228,299 | $342,589 | $121,796 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 112,584 | 106,258 | 99,868 | 86,014 | 85,139 |
| Common Shares | 1,122 | 1,011 | 997 | 859 | 851 |
| Retained earnings | -3,727,088 | -2,840,972 | -2,147,685 | -1,656,811 | -1,246,703 |
| Other shareholders' equity | -36,518 | -33,213 | -34,433 | -33,441 | 4,369 |
| TOTAL | $1,438,692 | $1,301,965 | $1,766,431 | $920,221 | $1,264,714 |
| Total Liabilities And Equity | $2,395,134 | $1,574,802 | $1,994,730 | $1,262,810 | $1,386,510 |